Skip to content

    Pain Management Health Center

    Font Size

    FDA Panel Rejects Vioxx-Like Pain Drug

    Experts Raise Concerns About Potential Safety Issues of Arcoxia
    WebMD Health News
    Reviewed by Louise Chang, MD

    April 12, 2007 -- A federal advisory panel on Thursday rejected Merck's bid to market a new osteoarthritis medication similar to Vioxx, a drug the company pulled from the U.S. market in 2004 because it put patients at risk for heart attacks and strokes.

    The decision, delivered in a 20 to 1 vote, makes it highly unlikely that the FDA will approve the drug, called Arcoxia.

    Arcoxia is in the class of nonsteroidal anti-inflammatory drugs (NSAIDs) known as Cox-2 inhibitors, which includes Vioxx and Bextra -- both removed from U.S. pharmacies -- as well as Celebrex, which is still on the market. Cox-2 drugs have a lower risk for stomach ulcers and gastrointestinal bleeding than other NSAIDs such as aspirin and ibuprofen.

    Arcoxia has been sold for the last five years in Europe and in dozens of countries around the world. The drug represented Merck's first attempt to return to the once-lucrative Cox-2 pain drug market in the U.S.

    The company had hoped to convince experts that the drug was a better pain drug than related drugs -- and also that it was safer.

    "Patients with osteoarthritis want and deserve additional treatment options," said Scott Korn, MD, Merck's executive director of regulatory affairs.

    But experts and some FDA officials criticized Merck for using poorly designed scientific studies in an attempt to put Arcoxia in the best possible light.

    Panel member David Felson, MD, noted that more than roughly 20 nonsteroidal anti-inflammatory drugs are already on the market.

    "A new drug has to have some reason why you would put it in the top six of your rotation or it's not going to have much of an effect," said Felson, a professor of medicine at the Boston University School of Medicine.

    After hearing Merck's results, Felson said he'd concluded that "20 is enough."

    Robert Shibuya, an FDA medical officer, told experts that studies in nearly 4,000 patients left "little doubt" that Arcoxia is an effective pain reliever. But in question was the drug's potential, like similar drugs, to increase risk for cardiovascular problems like heart attacks and stroke in millions of potential users.

    Today on WebMD

    pain in brain and nerves
    Top causes and how to find relief.
    knee exercise
    8 exercises for less knee pain.
    acupuncture needles in woman's back
    How it helps arthritis, migraines, and dental pain.
    chronic pain
    Get personalized tips to reduce discomfort.
    illustration of nerves in hand
    lumbar spine
    Woman opening window
    Man holding handful of pills
    Woman shopping for vegetables
    Sore feet with high heel shoes
    acupuncture needles in woman's back
    man with a migraine